Cargando…

Consequences of redefining Alzheimer's disease in terms of amyloid burden without regard to cognitive decline

Detalles Bibliográficos
Autores principales:	Robinson, Stephen R., Brothers, Holly M., Gosztyla, Maya L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199922/ https://www.ncbi.nlm.nih.gov/pubmed/30323134 http://dx.doi.org/10.4103/1673-5374.241456

Ejemplares similares

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
por: Brothers, Holly M., et al.
Publicado: (2018)

The Amyloid Cascade Hypothesis 2.0 for Alzheimer’s Disease and Aging-Associated Cognitive Decline: From Molecular Basis to Effective Therapy
por: Volloch, Vladimir, et al.
Publicado: (2023)

Repurposing verapamil for prevention of cognitive decline in sporadic Alzheimer's disease
por: Ahmed, Heba A., et al.
Publicado: (2021)

Redefining shared sanitation
por: Rheinländer, Thilde, et al.
Publicado: (2015)

Redefining Low Lead Levels
por: Iavicoli, Ivo, et al.
Publicado: (2011)

Redefining risk research priorities for nanomaterials
por: Grieger, Khara D., et al.
Publicado: (2009)

Redefining Genomic Privacy: Trust and Empowerment
por: Erlich, Yaniv, et al.
Publicado: (2014)

Redefining environmental exposure for disease etiology
por: Rappaport, Stephen M.
Publicado: (2018)

Redefining ARDS: a paradigm shift
por: Villar, Jesús, et al.
Publicado: (2023)

Redefining the hypotheses driving Parkinson’s diseases research
por: Farrow, Sophie L., et al.
Publicado: (2022)

Redefining precision radiotherapy through liquid biopsy
por: McLaren, D. B., et al.
Publicado: (2023)

PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer’s Disease
por: Camargo, Luana Cristina, et al.
Publicado: (2021)

Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
por: Osborne, Olivia M., et al.
Publicado: (2023)

Oxidative stress: culprit or consequence in Alzheimer’s amyloidopathy
por: Sharma, Chanchal, et al.
Publicado: (2023)

Redefining the endophenotype concept to accommodate transdiagnostic vulnerabilities and etiological complexity
por: Beauchaine, Theodore P, et al.
Publicado: (2017)

Redefining Prevention and Care: A Status-Neutral Approach to HIV
por: Myers, Julie E, et al.
Publicado: (2018)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Cognitive decline assessment in speakers of understudied languages
por: Hatahet, Oula, et al.
Publicado: (2023)

Poor Decision Making Is a Consequence of Cognitive Decline among Older Persons without Alzheimer’s Disease or Mild Cognitive Impairment
por: Boyle, Patricia A., et al.
Publicado: (2012)

Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
por: Huber, Colin M., et al.
Publicado: (2017)

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
por: Dansson, Hákon Valur, et al.
Publicado: (2021)

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
por: Wang, Xiaoqi, et al.
Publicado: (2020)

Primary prevention recommendations to reduce the risk of cognitive decline
por: Sabbagh, Marwan N., et al.
Publicado: (2022)

TDP-43 and amyloid precursor protein processing: implications for Alzheimer’s disease
por: Hicks, David A.
Publicado: (2020)

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
por: Ramanan, Vijay K., et al.
Publicado: (2023)

Modern Biophysics Redefines Our Understanding of Fungal Cell Wall Structure, Complexity, and Dynamics
por: Latgé, Jean-Paul, et al.
Publicado: (2022)

If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
por: Haass, Christian, et al.
Publicado: (2022)

A crate of Pandora: do amyloids from bacteria promote Alzheimer’s disease?
por: Nguyen, Vu Thu Thuy, et al.
Publicado: (2020)

The tip of the iceberg? The underestimated potential of non-canonical beta-amyloids for Alzheimer’s disease
por: Busch, Lukas, et al.
Publicado: (2023)

Determining Microbial Roles in Ecosystem Function: Redefining Microbial Food Webs and Transcending Kingdom Barriers
por: Handley, Kim M.
Publicado: (2019)

Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease
por: Malpetti, Maura, et al.
Publicado: (2020)

Principles of Design of Clinical Trials for Prevention and Treatment of Alzheimer’s Disease and Aging-Associated Cognitive Decline in the ACH2.0 Perspective: Potential Outcomes, Challenges, and Solutions
por: Volloch, Vladimir, et al.
Publicado: (2023)

What good is the reserve? A translational perspective for the managing of cognitive decline
por: Serra, Laura, et al.
Publicado: (2019)

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
por: Fessel, Jeffrey
Publicado: (2022)

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
por: Richard, Edo, et al.
Publicado: (2021)

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
por: Imbimbo, Bruno P., et al.
Publicado: (2022)

Misfolded amyloid-β strains and their potential roles in the clinical and pathological variability of Alzheimer’s disease
por: Kelley, Sara, et al.
Publicado: (2022)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
por: Kim, Jun Pyo, et al.
Publicado: (2021)

Considerations for the assessment of suicidal ideation and behavior in older adults with cognitive decline and dementia
por: Alphs, Larry, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g5si5b5kenbqq1iaes8pki52jt